Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 52-Week High – Here’s Why

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.25 and last traded at $13.1510, with a volume of 147952 shares changing hands. The stock had previously closed at $12.71.

Analyst Ratings Changes

Several analysts have recently weighed in on AMRX shares. JPMorgan Chase & Co. upped their price objective on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Piper Sandler reissued an “overweight” rating and issued a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Amneal Pharmaceuticals Stock Up 1.8%

The business’s 50 day simple moving average is $12.04 and its 200 day simple moving average is $10.17. The company has a market capitalization of $4.07 billion, a PE ratio of 647.57 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the sale, the director directly owned 291,029 shares in the company, valued at approximately $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the transaction, the executive vice president owned 146,403 shares in the company, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 231,856 shares of company stock worth $2,743,724 over the last three months. 17.45% of the stock is owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in shares of Amneal Pharmaceuticals by 187.1% during the third quarter. Assenagon Asset Management S.A. now owns 2,150,041 shares of the company’s stock worth $21,522,000 after acquiring an additional 1,401,190 shares in the last quarter. Westshore Wealth LLC acquired a new position in Amneal Pharmaceuticals in the 3rd quarter worth about $13,833,000. Allspring Global Investments Holdings LLC raised its stake in shares of Amneal Pharmaceuticals by 1,440.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after purchasing an additional 1,062,045 shares in the last quarter. Rubric Capital Management LP lifted its holdings in shares of Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after buying an additional 974,355 shares during the last quarter. Finally, Woodline Partners LP grew its stake in shares of Amneal Pharmaceuticals by 165.2% in the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company’s stock valued at $12,604,000 after buying an additional 937,035 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.